Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/174306
Title: The Ethyl Acetate Extract of Leaves of Ugni molinae Turcz. Improves Neuropathological Hallmarks of Alzheimer's Disease in Female APPswe/PS1dE9 Mice Fed with a High Fat Diet
Author: Jara, Daniela
Castro-Torres, Rubén Darío
Ettcheto Arriola, Miren
Auladell i Costa, M. Carme
Kogan, Marcelo J.
Folch, Jaume
Verdaguer Cardona, Ester
Cano Fernández, Amanda
Busquets Figueras, Oriol
Delporte, Carla
Camins Espuny, Antoni
Keywords: Malaltia d'Alzheimer
Malalties neurodegeneratives
Àcid acètic
Alzheimer's disease
Neurodegenerative Diseases
Acetic acid
Issue Date: 1-Nov-2018
Publisher: IOS Press
Abstract: The most common type of dementia is Alzheimer's disease (AD), a progressive neurodegenerative disease characterized by impairment in cognitive performance in aged individuals. Currently, there is no effective pharmacological treatment that cures the disease due to the lack of knowledge on the actual mechanisms involved in its pathogenesis. In the last decades, the amyloidogenic hypothesis has been the most studied theory trying to explain the origin of AD, yet it does not address all the concerns relating to its development. In the present study, a possible new preclinical treatment of AD was evaluated using the ethyl acetate extract (EAE) of leaves of Ugni molinae Turcz. (synonym Myrtus ugni Molina Family Myrtacea). The effects were assessed on female transgenic mice from a preclinical model of familial AD (APPswe/PS1dE9) combined with a high fat diet. This preclinical model was selected due to the already available experimental and observational data proving the relationship between obesity, gender, metabolic stress, and cognitive dysfunction; related to characteristics of sporadic AD. According to chemical analyses, EAE would contain polyphenols such as tannins, flavonoid derivatives, and phenolic acids, as well as pentacyclic triterpenoids that exhibit neuroprotective, anti-inflammatory, and antioxidant effects. In addition, the treatment evidenced its capacity to prevent deterioration of memory capacity and reduction of progression speed of AD neuropathology.
Note: Reproducció del document publicat a: https://doi.org/10.3233/JAD-180174
It is part of: Journal of Alzheimer's Disease, 2018, vol. 66, num. 3, p. 1175-1191
URI: http://hdl.handle.net/2445/174306
Related resource: https://doi.org/10.3233/JAD-180174
ISSN: 1387-2877
Appears in Collections:Articles publicats en revistes (Farmàcia, Tecnologia Farmacèutica i Fisicoquímica)
Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)
Articles publicats en revistes (Biologia Cel·lular, Fisiologia i Immunologia)

Files in This Item:
File Description SizeFormat 
682949.pdf1.93 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.